Premium
MALDI‐MS derived prognostic protein markers for resected non‐small cell lung cancer
Author(s) -
Xu Baogang J.,
Gonzalez Adriana L.,
Kikuchi Takefumi,
Yanagisawa Kiyoshi,
Massion Pierre P.,
Wu Huiyun,
Mason Stephen E.,
Olson Sandy J.,
Shyr Yu,
Carbone David P.,
Caprioli Richard M.
Publication year - 2008
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.200800094
Subject(s) - immunohistochemistry , lung cancer , staining , medicine , lymph node , pathology , oncology , pathological , lung
Protein signals obtained directly from frozen lung tissue sections using MALDI‐MS were used to predict nodal involvement and survival in resected non‐small cell lung cancer (NSCLC). We have identified a list of these protein signals and further evaluated their prognostic values for NSCLC using immunohistochemistry (IHC). Kaplan‐Meier analysis was used to assess the mortality risk associated with the prognostic protein IHC‐staining intensities. The combined IHC scores of calmodulin, thymosin β4, and thymosin β10 were found to be correlated with NSCLC patient survival ( p = 0.004). Furthermore, low cofilin‐1 IHC‐staining intensity was found to be correlated with a better outcome for patients with negative lymph node status ( p = 0.006) while high cofilin‐1 IHC‐staining intensity was found to be correlated with a better outcome for patients with positive node status ( p = 0.034). In conclusion, the prognostic protein signals selected using MALDI‐MS can be identified and tested by IHC in formalin‐fixed tissue samples. MALDI‐MS‐derived protein signals can be potentially translated to a conventional clinical setting to aid in the prognosis of patients with NSCLC at the molecular level.